R&D From in silico to in vivo: Why development strategy now dete... As discovery becomes faster and more accessible, the differentiator shifts downstream.
Sales & Marketing Breaking tradition to reimagine medical affairs workflows fo... To stay relevant, medical affairs teams must adapt how they work to meet new demands with greater agility and efficiency.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
